Influenza A Virus, H3N2 Subtype
"Influenza A Virus, H3N2 Subtype" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.
| Descriptor ID |
D053122
|
| MeSH Number(s) |
B04.820.545.405.400.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Influenza A Virus, H3N2 Subtype".
Below are MeSH descriptors whose meaning is more specific than "Influenza A Virus, H3N2 Subtype".
This graph shows the total number of publications written about "Influenza A Virus, H3N2 Subtype" by people in this website by year, and whether "Influenza A Virus, H3N2 Subtype" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2007 | 4 | 0 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 2 | 1 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 4 | 5 |
| 2017 | 4 | 1 | 5 |
| 2018 | 2 | 5 | 7 |
| 2019 | 2 | 2 | 4 |
| 2020 | 3 | 5 | 8 |
| 2021 | 0 | 12 | 12 |
| 2022 | 1 | 4 | 5 |
| 2023 | 1 | 5 | 6 |
| 2024 | 2 | 8 | 10 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Influenza A Virus, H3N2 Subtype" by people in Profiles.
-
Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. J Infect Dis. 2025 Feb 04; 231(1):e123-e131.
-
Pediatric Clinical Influenza Disease by Type and Subtype 2015-2020: A Multicenter, Prospective Study. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).
-
Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection. J Infect Dis. 2024 Dec 16; 230(6):1309-1318.
-
Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. Lancet Microbe. 2025 Feb; 6(2):100935.
-
Elevated body mass index is not significantly associated with reduced influenza vaccine effectiveness. Sci Rep. 2024 09 13; 14(1):21466.
-
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
-
Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses. 2024 Jun; 18(6):e13342.
-
Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients. Blood Adv. 2024 04 23; 8(8):1880-1892.
-
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis. 2024 Apr 10; 78(4):1056-1064.
-
Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network. Clin Infect Dis. 2024 03 20; 78(3):746-755.